Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 81, Issue 3, 2008, Pages 338-344

  Tanimura, Kyoko ^a   Nakajima, Yasushi ^a   Nagao, Mototugu ^a   Ishizaki, Akira ^a   Kano, Toshiko ^a   Harada, Taro ^a   Okajima, Fumitaka ^a   Sudo, Mariko ^a   Tamura, Hideki ^a   Ishii, Shinya ^a   Sugihara, Hitoshi ^a   Yamashita, Shizuya ^b   Asai, Akira ^a   Oikawa, Shinichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein B48; Carotid plaque; Diurnal change; ELISA; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B48; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN B-48; BLOOD PRESSURE; CAROTID STENOSIS; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 48949084729     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.028     Document Type: Article

References (29)

1. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3 (1996) 213-219
2. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
3. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 153 (2001) 490-499
4. Criqui M.H., Heiss G., Cohn R., Cowan L.D., Suchindran C.M., Bangdiwala S., et al. Plasma triglyceride level and mortality from coronary heart disease. N. Engl. J. Med. 328 (1993) 1220-1225
5. Wilhelmsen L., Wedel H., and Tibblin G. Multivariate analysis of risk factors for coronary heart disease. Circulation 48 (1973) 950-958
6. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 (2007) 299-308
7. Mero N., Malmström R., Steiner G., Taskinen M.R., and Syvänne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 150 (2000) 167-177
8. Meyer E., Westerveld H.T., de Ruyter Meijstek F.C., van Greevenbroek M.M., Rienks R., van Rijn H.J., et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 124 (1996) 221-235
9. Karpe F., de Faire U., Mercuri M., Bond M.G., Hellénius M.L., and Hamsten A. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 141 (1998) 307-314
10. Sakai N., Sugimoto T., Tsujii K., Hiraoka H., Nakamura T., Yamashita S., et al. Fasting serum apolipoprotein (apo) B-48 levels measured by a novel ELISA are a simple and useful marker for postprandial hyperlipidemia and predict coronary heart disease (CHD). Circulation 110 Suppl. III (2004) III-183
11. Boquist S., Ruotolo G., Tang R., Björkegren J., Bond M.G., de Faire U., et al. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 100 (1999) 723-728
12. Valero R., Lorec A.M., Paganelli F., Beliard S., Atlan C., Lairon D., et al. Fasting apoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia. Metabolism 54 (2005) 1442-1447
13. Jackson K.G., and Williams C.M. Apolipoprotein B-48: comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 176 (2004) 207-217
14. Sakai N., Uchida Y., Ohashi K., Hibuse T., Saika Y., Tomari Y., et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J. Lipid Res. 44 (2003) 1256-1262
15. Uchida Y., Kurano Y., and Ito S. Establishment of monoclonal antibody against human Apo B-48 and measurement of ApoB-48 in serum by ELISA method. J. Clin. Lab. Anal. 12 (1998) 289-292
16. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
17. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46 (2003) 733-749
18. Curtin A., Deegan P., Owens D., Collins P., Johnson A., and Tomkin G.H. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol. 33 (1996) 205-210
19. Hogue J.C., Lamarche B., Tremblay A.J., Bergeron J., Gagné C., and Couture P. Evidence of increased secretion of apolipoprotein B-48-containig lipoproteins in subjects with type 2 diabetes. J. Lipid Res. 48 (2007) 1336-1342
20. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
21. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., et al. Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis. Diagnostic criteria for Dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular disease for Japanese. J. Atheroscler. Thromb. 14 (2007) 155-158
22. Flood C., Gustafsson M., Richardson P.E., Harvey S.C., Segrest J.P., and Borén J. Identification of the proteoglycan binding site in apolipoprotein B48. J. Biol. Chem. 277 (2002) 32228-32233
23. Fujioka Y., Cooper A.D., and Fong L.G. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J. Lipid Res. 39 (1998) 2339-2349
24. Brown M.L., Ramprasad M.P., Umeda P.K., Tanaka A., Kobayashi Y., Watanabe T., et al. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7488-7493
25. Kawakami A., Tani M., Chiba T., Yui K., Shinozaki S., Nakajima K., et al. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 424-429
26. Proctor S.D., and Mamo J.C. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1595-1600
27. Pal S., Semorine K., Watts G.F., and Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin. Chem. Lab. Med. 41 (2003) 792-795
28. Spence J.D., Eliasziw M., DiCicco M., Hackam D.G., Galil R., and Lohmann T. Carotid plaque area. A tool for targeting and evaluating vascular preventive therapy. Stroke 33 (2002) 2916-2922
29. Campos H., Khoo C., and Sacks F.M. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis 181 (2005) 345-351